Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo Patients who received SNG001 were more than twice as likely to recover from COVID-19
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company, is delighted to announce participation in the recently notified funding initiative for COVID-19 clinical trials by the medical research
The University of Dundee is leading the clinical trial of a new anti-inflammatory drug it is hoped may reduce instances of severe lung damage and death in Covid-19 patients.
Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio
